Skip to content

Effects of different treatment (metformin, spironolactone, GLP-1 receptor agonist. etc) on clinical and endocrine features and the levels of adipocytokine in patients with polycystic ovary syndrome.

Effects of different treatment (metformin, spironolactone, GLP-1 receptor agonist. etc) on clinical and endocrine features and the levels of adipocytokine in patients with polycystic ovary syndrome.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16008084
Enrollment
Unknown
Registered
2016-03-13
Start date
2015-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

Sponsors

The third affiliated hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: All PCOS patients met all three criteria of the revised 2003 Rotterdam European Society of Human Reproduction and Embryology (ESHRE)/American Society of Reproductive Medicine (ASRM) PCOS Consensus Workshop Group diagnostic criteria. The three criteria are 1. oligo- and/or anovulation; 2. clinical and/or biochemical signs of hyperandrogenism, and 3. ultrasound appearance of polycystic ovaries with the exclusion of other known causes of hyperandrogenemia and ovulatory dysfunction including 21-hydroxylase deficiency, congenital adrenal hyperplasia, Cushings syndrome, androgensecreting tumors, thyroid disease, and hyperprolactinemia.

Exclusion criteria

Exclusion criteria: Exclusion criteria for all groups included age > 40 years, or <18 years. PCOS combined with other causes of infertility, known cardiovascular disease, thyroid disease, smoking, diabetes, hypertension. Exclude patients with obvious signs and symptoms of liver and kidney disease, or with a history of drug abuse and alcohol abuse over the past 2 years, or with a history of mental illness, or with infection, trauma, surgery and other emergency situation. Also exclude patients who could not take effective contraceptive measures through the study, or applied with metformin or other euglycemic agent one month before the inclusion or receiving steroid therapy or treatment of malignant tumor.

Design outcomes

Primary

MeasureTime frame
insulin resistence;glucolipids metabolism index;sex hormone levels;Insulin resistance and beta-cell function level;

Secondary

MeasureTime frame
anthropometric measurements;menstrual cycle;Fat factor levels;The inflammatory factor level;

Countries

China

Contacts

Public ContactZhang Ying

The third affiliated hospital of Guangzhou Medical University

zhangying30412@163.com+86 18928916685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026